genenta science



GENENTA TRANSFORMATION INTO SAENTRA FORGE

The Next-Generation Strategic Industrial Consolidator in Biotech, Defense, Aerospace, National Security.

February 2026

FORWARD-LOOKING STATEMENTS AND OTHER NOTICES

Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation e are forward-looking statements. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta Science’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech, the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM or any other studies, as well as Genenta’s ability to establish partnerships and fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024, and Genenta's material disclosures on Form 6-K dated January 26, 2026, and other Form 6-Ks filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.

LEADERSHIP

PIERLUIGI PARACCHI

Chairman, CEO & Founder

Chairman of **Praexidia Foundation** and **Praexidia Industrie Strategiche**, Moderator of the **National Working Table for the Internationalization of Biotechnology Sector**, promoted by the Foreign Ministry. Member of the Board of Guarantors of the Italian Academy at Columbia University, NY.
Member of the **Assobiotec** Executive Committee, Italy's national association of biotech companies.
Previously, as a venture capitalist, he was Founder & CEO of **Quantica SGR**, Co-Founder of **Axòn Capital**, and Venture Consultant at **Sofinnova Partners**, achieving over $400 million in exits and raising more than $200 million in venture funding.

+ 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic, and life science companies, including **Biological Dynamics**, **GenMark Diagnostics** (now part of Roche), and **C-N Biosciences** (now part of Merck). He also serves on the Board of Directors of several private high-technology companies, including **Nuclear RNA Networks**, an early-stage RNA gene transcription therapeutics company, and **Parabilis Space Technologies**, a global leader in hybrid solid-liquid rocket motors shaping the next era of responsive space operations. Raised $500MM+ in equity and debt capital in public and private offerings. He holds a B.S. from the University of Pennsylvania (Wharton School), MBA from the University of Arizona (Eller School).

RICHARD B. SLANSKY

M.D., Ph.D., Board Member, Chief Medical Officer and Head of Development

FRANCESCO GALIMI

M.D., Ph.D., Board Member, serving as Chief Medical Officer and Head of Development

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotech as well as large pharma companies. Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio**. Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at **GNF/Novartis**. Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

20 years of experience in life sciences R&D encompassing oncology, drug development, and cell and gene therapy — she has collaborated with various pharmaceutical companies and academic institutions. She earned a Master's degree in Medical Biotechnology and a second-level vocational Master's in Pharmacy and Pharmaceutical Oncology from the University of Milan. Additionally, she completed a Ph.D. in Molecular and Cellular Biology at **Vita-Salute San Raffaele University**. She is also a member of the **European Academy of Tumor Immunology (EATI)**.

STEFANIA MAZZOLENI

Ph.D., Director of Program Development

GIANFRANCO DE NIGRIS

Vice President Corporate Development

He is in charge of strategic corporate initiatives, investor relations, and long-term financing planning. Acting as the primary interface with global institutional investors, analysts, and investment banks, he strengthens the company's market visibility and ensures alignment around its equity story.
Before joining Genenta, Gianfranco held roles in leading financial institutions. His background spans financial advisory, wealth management, and investment banking, with expertise in valuation, investment strategy, and client advisory.
He holds a Master's degree from **Bocconi University**.

Highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation. Prior to joining Genenta, she was Head of Finance at **OAM** – Financial Supervisory Authority, and she held CFO roles and was part of the Supervisory Body ex DLGS 231/01 of a public company in the renewable energy field. Former senior manager at **PWC**, in the industrial and service field. She earned a Master's degree at the University of Nicosia in Science of Digital Currency, a Degree as Strategic CFO at Harvard Business School, a Master's degree in Business and Administration at the University of Parma and she is a Chartered Public Accountant and Auditor.

BARBARA REGONINI

Finance Director

GENENTA TRANSFORMATION INTO SAENTRA FORGE

In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A. (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a **next-generation strategic industrial consolidator** focused on acquiring **privately held businesses** operating in national-security **regulated sectors** contemplated by the Italian Golden Power legislation[1].

The Company intends to target **majority ownership in companies with established operating profitability**, typically generating up to approximately €5 million in EBITDA.

In this context, Genenta plans to adopt the new corporate name of **Saentra Forge S.p.A.** with a new Nasdaq ticker symbol of **SAEN[2]**.

1: Golden Power is Italy's investment screening framework — broadly comparable to CFIUS in the United States, the IEF regime in France, and the United Kingdom's NSI Act — and covers strategic domains such as biotechnology, biosecurity, defense, cybersecurity, AI-driven intelligence, aerospace, quantum technologies, secure communications, and critical infrastructure.
2: The new corporate name and the new Nasdaq ticker symbol will become effective upon approval by its shareholders at a Shareholders' Meeting scheduled for March 25-26, 2026.

SAENTRA FORGE STRATEGIC PILLARS

The Company will be organized around key synergistic pillars

BIOTECHNOLOGY



DEFENSE



AEROSPACE

NATIONAL SECURITY

built through strategic majority acquisitions, creating a diversified platform.

genenta science

- DEFENSE
- AEROSPACE
- NATIONAL SECURITY

genenta science

DEFENSE, AEROSPACE, NATIONAL SECURITY

Saentra Forge's defense and advanced manufacturing pillar will be built through the acquisition of **multiple privately held businesses** operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility.

First Integration: ATC, an Italian company operating as **high-precision manufacturer of tactical rifles and special-forces weapon systems, and competition-grade sporting firearms.**

ATC FIRST INTEGRATION: COMPANY OVERVIEW

- ATC "Armi Tattiche Custom" is an Italian company **founded in 2019.** ATC designs, engineers, and manufactures **high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories.** Through vertical integration of design and through final quality assurance, ATC provides fully customized, premium tactical systems. Its location in Northern Italy gives it access to advanced mechanical engineering talent and streamlined export logistics.
- ATC conducts its core operations in Italy, including R&D, CAD/CAM design, precision CNC machining, finishing, assembly, and final tomographic inspection.
- ATC holds UAMA, SeRNI export-control licenses, NATO qualifications and authorization from the Italian Ministry of Defense[1].
- They market under **"Made in Italy"** positioning, with the ability to deliver "custom" configurations to clients.
- ATC has established a commercial agreement in **Sofia (Bulgaria)** and is poised for the upcoming opening of a production plant in **Miami (USA).**
- ATC products are used by special-forces units and include **combat-proven systems.** FY26 revenues are expected to be primarily driven by defense-related activities, including contracts with key institutional customers, notably in Ukraine.

1: UAMA is the Italian government authority responsible for authorizing and overseeing the export and transfer of defense-related materials under applicable Italian and international regulations.
SeRNI: SeRNI, the Italian National Register of Defense and National Security Companies, certifies authorized defense and national security operators. North Atlantic Treaty Organization

ATC INTEGRATION: KEY FIGURES

- Genenta has entered into a binding agreement according to which it will provide funding for ATC through a **series of reserved capital increases, via a performance-based and staged acquisition** to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received the required clearance under the **Golden Power** regulatory framework. Genenta expects to fund a total of **EUR 5.1 million** in several performance-driven tranches.
- ATC is projecting **revenues** of approximately **€4.0 million in 2026,** increasing to around **€9.0 million by 2027**. The company operates with a **solid net cash position** and **no outstanding bank debt,** reflecting a disciplined management structure. On the profitability side, ATC forecasts **EBITDA** of more than **€2.0 million in 2026,** with management expecting EBITDA to approximately **double in 2027**.
- In addition, ATC anticipates closing 2026 with a positive cash balance exceeding €2.0 million and expects to further strengthen its liquidity position by ending 2027 with cash exceeding €5.0 million.

genenta science

BIOTECHNOLOGY

GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY

Proprietary platform to provide durable and safe treatments for solid tumors

Temferon ™ is a one-time cell therapy designed to break the tumor-induced immune suppression by enabling sustained targeted expression of **therapeutic payload inside the tumor microenvironment (TME).**

Generating clinical proof of concept for breaking immune tolerance

TEM GBM Phase 1/2a study:

- **Phase 1 dosing completed** with 25 patients receiving Temferon.
- Favorable initial evidence of reprogramming of the tumor microenvironment.
- Potential ability to activate T cells which could then be enhanced by the use of immune checkpoint inhibitors.
- **Two patients** have been enrolled in the **TEM-LT long-term follow-up study, surviving three years** from the time of 1st surgery.

SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS

Evaluable Patients Dosed with Temferon	25
Number of Patients survival > 1 year	19 (76%)
Number of Patients survival > 2 years[1]	8 (32%)
Number of Patients survival > 3 years	2 (8%)

Survival rate at 1 and 2 years since first surgery compared favorably with reference GBM Italian registry data[2] (56.4% alive at 1 year, 14.4% alive at 2 years), indicating a potential survival benefit in the TEM-GBM treated cohort.

1 – Data as of January 20, 2026.

2 – Tumor registry of Istituto Nazionale Carlo Besta, Italy - Courtesy of Dr. Eoli.

GENENTA SCIENCE: PARTNERSHIP TO TAKE TO THE NEXT STAGE

PARTNERSHIPS TO TAKE TO NEXT STAGE

The Company has reached **key clinical milestones** that it believes will now enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and strategic value. **DC Advisory** has been engaged to serve as the Company's **exclusive financial advisor for partnership initiatives.** Such initiatives are envisaged to prioritize leveraging the technology platform for broader applications and indications, particularly in solid tumors that are inherently difficult to target, while pursuing combination therapy approaches, or continuing development of Temferon as a glioblastoma multiforme (GBM) monotherapy. During this process, the Company will continue to advance its trial in GBM, pursue a **capital-efficient approach** to advancing additional opportunities through partnerships and does not plan to internally advance the GU study and other clinical trials at this time.

HARNESSING THE POWER OF STEM CELLS WHILE INCORPORATING miRNA

Tie2-Expressing Monocytes (TEMs)

Circulate low frequency



Recruited into tumors



De Palma et al. Nature Med 2003;
De Palma et al. Cancer Cell 2005 & 2008;
Pucci et al. Blood 2009
Mazzieri et. al. Cancer Cell 2011

- Pro tumoral associated macrophage subset.
- Perivascular localization.
- Angiogenic & tissue remodeling function.
- Genetic ablation curbs tumor growth.



Tissue remodeling macrophage (TEM)

Immune-activating macrophage («synthetic» TEM)

TEMFERON DELIVERS IFN-α WITHIN THE TUMOR MICROENVIRONMENT

Single Temferon treatment potentially renders solid tumors visible to the immune system



Tie2 monocytes coupled with miRNA126 enable targeted payload delivery inside solid tumors

TEMFERON AT A GLANCE

TEMFERON

Frozen autologous hematopoietic stem and progenitor cells (CD34+) transduced ex-vivo with a third generation LVV to drive myeloid-specific IFN-α2 expression.

FORMULATION

Cryopreserved intravenous injectable solution.

DURABILITY OF RESPONSE

Potentially life-long.

PLATFORM PROOF-OF-CONCEPT INDICATION

Solid tumors: μMGMT GBM.

MECHANISM OF ACTION

Direct: anti-proliferative, anti-angiogenic;
Indirect: immune system re-programming, CD8+ T cells recruitment, T cells exhaustion counteraction.

TEMFERON: OVERCOMING IMMUNO-ONCOLOGY BARRIERS VIA TARGETED, TUMOR-AGNOSTIC IMMUNE ACTIVATION

DEMONSTRATED DURABILITY

CD14



HSCs enable the maintenance of a potential **long-term tumor protection** by creating a **life-long drug reservoir.**

SELECTIVE DELIVERY WITHIN THE TUMOR MICROENVIRONMENT

Tie2 macrophages (TEMs)



Recruited into Tumors



De Palma et al, Nature Med 2003;
De Palma et al, Cancer Cell 2005 & 2008
Pucci et al, Blood 2009
Mazzieri et al, Cancer Cell 2011

TEMs, being recruited by growing tumors, enable the **payload delivery** within the **TME.**

PREVENT SYSTEMIC TOXICITY

Peripheral Blood



The miRNA post-transcriptional regulation limits the systemic **payload exposure.**

ACTIVATE IMMUNE SYSTEM

Genenta cell-based platform (IFN-α)



IFN-α deployment by TEMs, both in **pre-clinical and clinical** setting favors the **myeloid proinflammatory** state.

PRELIMINARY CLINICAL DATA IN µMGMT GBM

SAFETY AND TOLERABILITY

- Detectable and expectedly very **low levels of IFN-α** (pg/ml range) in plasma;
- **Manageable safety profile,** with adverse events commonly associated with autologous stem cell transplantation and glioblastoma;
- **No dose limiting toxicities** observed to date;
- Rapid engraftment and **hematological recovery** observed in all patients treated (n=25).

BIOLOGICAL ACTIVITY

- Temferon-derived cells were **detectable** at more than 24 months **post infusion;**
- **Temferon** progeny detected **inside the GBM** tumor;
- Intra-tumor **IFN-α release;**
- Evidence of a pro-inflammatory state in recurrent tumors from patients who underwent second surgery;
- **Reprogramming** of the myeloid compartment.

PIERLUIGI PARACCHI, CEO

pierluigi.paracchi@genenta.com

www.genenta.com

Via dell’Annunciata 31 - 20121 Milan, Italy

APPENDIX

BOARD OF DIRECTORS

PIERLUIGI PARACCHI

Chairman, CEO & Founder

Chairman of **Praexidia Foundation and Praexidia Industrie Strategiche,** Moderator of the National Working Table for the **Internationalization of Biotechnology Sector, promoted by the Foreign Ministry**.

Member of the **Assobiotec** Executive Committee, the National Association of biotech companies.

Co-Founder & Board Member **Altheia Science**, Previously, as a venture capitalist, he was Founder & CEO of **Quantica SGR**, Co-Founder of **Axòn Capital**, and Venture Consultant at Sofinnova Partners, achieving over $400 million in exits and raising more than $200 million in venture funding.

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotechs as well as large pharma companies.

Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio.**

Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at GNF/Novartis.

Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

FRANCESCO GALIMI

M.D., Ph.D., Board Member, serving as Chief Medical Officer and Head of Development

MIGUEL M. MUTTI

Board member

Senior executive with over 25 years of international experience in the pharmaceutical and investment banking sectors. He has a proven track record in corporate and business development, M&A, licensing, and general management, having led major growth, restructuring, and integration projects across Europe, Latin America, and Asia.

Currently, he serves as Managing Partner at **Sinergetica Healthcare**, a strategic consulting and investment firm focused on pharma, biotech, and medtech. Before that, he held senior leadership roles at **Lupin Limited, Grünenthal GmbH, Chemo Group, and Citigroup.**

Miguel combines strategic vision, financial expertise, and hands-on operational leadership, supported by an MBA from ISTUD and executive training at INSEAD.

Giacomo Paracchi is a business lawyer with extensive experience as General Counsel and Head of Legal & Corporate Affairs within structured multinational groups.

Board Member of **Praexidia Foundation** and **Praexidia Industrie Strategiche.**

Since September 2023, he has been serving as General Counsel of the **Geodis Group**, and since May 2025, he joined **LEXIA** as a Partner in the Corporate / M&A / Capital Markets Department.

Previously, he held senior legal and corporate positions at **Comifar Group**, **Valtellina Group, and Techint Group,** overseeing legal, corporate affairs, and compliance functions.

GIACOMO PARACCHI

Board member

ARMON R. SHAREI

Ph.D., Board Member

Armon is Founder and CEO of **Portal Biotechnologies** and formerly CEO and Founder of **SQZ Biotechnologies** (NYSE: SQZ).

He led company from invention to post-IPO with over $300M in equity financing, $1Bn **Roche** collaboration, and three clinical trials.

Stanford University, CA BS, with Honors and Distinction in Chemical Engineering and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology. Post-Doctoral Fellow, Immunology at Harvard Medical School.

FINANCIAL PROFILE

Cash & cash equivalents and marketable securities[1]	$ 33 MM
Expected cash runway[2]	More than 12 months
Number of shares outstanding[3]	23.4 MM
Average volume[4]	721K shares

1 – Estimated (unaudited) at December 31, 2025.
2 - The complete documentation with respect to the Mandatory Convertible Bond is available in the Company's Form 6-K filing on the Company's website at www.genenta.com.
3 – As of December 31, 2025.
4 - At December 31, 2025 according to Yahoo Finance's key statistics listing.